stockrowProtagonist Therapeutics, Inc.
PTGX Healthcare Biotechnology
Protagonist Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, down 89.4% from fiscal 2024.
- Revenue
- +3,749.2%
- EPS
- +549.1%
- Free cash flow
- +839.7%
Quarter to June 2026, against a year earlier
Follow PTGX
Alert me
Protagonist Therapeutics, Inc. (PTGX) Return on equity
Protagonist Therapeutics, Inc.'s return on equity over the twelve months to 30 June 2026 was 11.0%, up 31.2 percentage points from fiscal 2025 (−20.2%). Over the past ten years it has ranged from −125.5% (fiscal 2016) to 74.3% (fiscal 2015); the current reading is higher than 82% of that period. That is above the Biotechnology industry median of −50.1% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −20.2% | (74.57) |
| FY2024 | 54.4% | 82.98 |
| FY2023 | −28.6% | 20.82 |
| FY2022 | −49.4% | (6.09) |
| FY2021 | −43.3% | (6.53) |
| FY2020 | −36.8% | 43.41 |
| FY2019 | −80.2% | (46.81) |
| FY2018 | −33.4% | 2.11 |
| FY2017 | −35.5% | 89.96 |
| FY2016 | −125.5% | (199.71) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| CYTK Cytokinetics, Incorporated compare | 184.7% |
| IBRX ImmunityBio, Inc. compare | 122.9% |
| TGTX TG Therapeutics, Inc. compare | 100.3% |
| KRYS Krystal Biotech, Inc. compare | 17.5% |
| PTGX Protagonist Therapeutics, Inc. | 11.0% |
| CAI Caris Life Sciences,�Inc. compare | 0.00% |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −24.8% |
| TWST Twist Bioscience Corporation compare | −29.6% |
| SYRE Spyre Therapeutics, Inc. compare | −41.2% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on PTGX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement